Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular-kidney-metabolic conditions: A pooled analysis of randomised trials.

ABSTRACT:

Background

Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co-transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD). Patients with low- or without albuminuria have been underrepresented in randomised clinical trials (RCTs), and the effects of SGLT2i on cardiovascular and kidney outcomes across the full range of albuminuria require further investigation.

Aims

To study the effects of SGLT2i on kidney and cardiovascular outcomes across albuminuria levels in populations with different cardiovascular-kidney-metabolic (CKM) risk.

Methods

Individual-patient data pooled analysis of RCTs across the CKM spectrum. Outcomes were studied across

SUBMITTER: Ferreira JP 

PROVIDER: S-EPMC12803639 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature